Results 11 to 20 of about 11,948 (164)

Review of Herpes Zoster Occurrence in Patients With Atopic Dermatitis Treated With JAK Inhibitors. [PDF]

Clin Transl Sci
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory skin disease that markedly impairs quality of life. Janus kinase inhibitors (upadacitinib, abrocitinib, and baricitinib) are effective therapies for moderate‐to‐severe AD but are associated with viral reactivation, particularly herpes zoster (HZ), due to immunosuppressive effects on interferon ...
Mandecka A, Perlak K, Bajek W, Kruczek W, Frątczak A, Polak K, Miziołek B, Bergler-Czop B.   +7 more
europepmc   +2 more sources

Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on Baricitinib

Rheumatology and Therapy, 2020
Introduction The objective of this study was to evaluate treatment patterns in patients with rheumatoid arthritis (RA), with a focus on the utilization of baricitinib, an oral highly selective Janus kinase 1 and 2 inhibitor, in an Italian real-world ...
Valentina Perrone, Serena Losi, Veronica Rogai, Silvia Antonelli, Walid Fakhouri, Massimo Giovannitti, Elisa Giacomini, Diego Sangiorgi, Luca Degli Esposti   +8 more
doaj   +1 more source

Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19

Frontiers in Medicine, 2021
Background: Baricitinib is a Janus kinase (JAK) inhibitor with a broader anti-inflammatory activity than tocilizumab and an antiviral potential although no head-to-head trials are available.
Mar Masiá, Sergio Padilla, José Alberto García, Javier García-Abellán, Andrés Navarro, Lucía Guillén, Guillermo Telenti, Paula Mascarell, Ángela Botella, Félix Gutiérrez   +9 more
doaj   +1 more source

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE

Rheumatology and Therapy, 2020
Introduction Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK 2, which has demonstrated significant efficacy in patients with moderately to severely active rheumatoid arthritis (RA).
Yue Yang, Xing-Fu Li, Xiao Zhang, Chun-De Bao, Jian-Kang Hu, Jian-Hua Xu, Xiang-Pei Li, Jian Xu, Dong-Yi He, Zhi-Jun Li, Guo-Chun Wang, Han-Jun Wu, Fei Ji, Lu-Jing Zhan, Cristiano A. F. Zerbini, Zhan-Guo Li   +15 more
doaj   +1 more source

Crosstalk between the JAK2 and TGF-β1 signaling pathways in scleroderma-related interstitial lung disease targeted by baricitinib

Advances in Rheumatology, 2023
Background and objective Systemic sclerosis (SSc) is an immune-mediated rheumatic disease characterized by fibrosis and vascular lesions. Interstitial lung disease is an early complication of SSc and the main cause of death from SSc. Although baricitinib
Dandan Wang, Yimei Wei, Lulu Xu, Jie Zhang   +3 more
doaj   +1 more source

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison

RMD Open, 2020
Objective To compare improvement in pain and physical function for patients treated with baricitinib, adalimumab, tocilizumab and tofacitinib monotherapy from randomised, methotrexate (MTX)-controlled trials in conventional synthetic disease-modifying ...
P Emery, M Van de Laar, R Fleischmann, B Fautrel, P C Taylor, I De La Torre, B Zhu, F De Leonardis, C L Kannowski, C Nicolay, Z Kadziola   +10 more
doaj   +1 more source

Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro

Dose-Response, 2022
Objective To evaluate the clinical efficacy and safety of baricitinib, a Janus kinase (JAK) inhibitor, in treating patient with progressing vitiligo, and to further explore the regulation of baricitinib on melanocytes (MCs) in vitro.
Jie Dong, Xuan Huang, Li-Ping Ma, Fei Qi, Si-Nian Wang, Zi-Qin Zhang, Shi-Nan Wei, Ling Gao, Fang Liu   +8 more
doaj   +1 more source

Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis

European Journal of Case Reports in Internal Medicine, 2019
Objectives: Baricitinib is an orally active Janus kinase (JAK) inhibitor used in the treatment of moderate to severe rheumatoid arthritis (RA). Materials and methods: Here, we report the case of a 56-year-old Caucasian male diagnosed with RA who ...
Dimitra Koumaki, Vasiliki Koumaki, George Bertsias, Eleni Lagoudaki, George Bertsias   +4 more
doaj   +1 more source

Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysis

Frontiers in Medicine
IntroductionBaricitinib is a selective inhibitor of Janus kinase (JAK)1 and JAK2, which is associated with clinical improvement in non-severe COVID-19 patients.
Yanxiong Mao, Anyi Guo, Ying Zhang, Jianxing Lai, Dian Yuan, Hao Zhang, Wenqi Diao, Weisong Chen, Fugui Yan   +8 more
doaj   +1 more source

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis

Arthritis Research & Therapy, 2021
Objective To compare the efficacy and safety of tofacitinib and baricitinib in patients with RA in a real-world setting. Methods A total of 242 patients with RA who were treated with tofacitinib (n = 161) or baricitinib (n = 81) were enrolled.
Naoki Iwamoto, Shuntaro Sato, Shota Kurushima, Toru Michitsuji, Shinya Nishihata, Momoko Okamoto, Yoshika Tsuji, Yushiro Endo, Toshimasa Shimizu, Remi Sumiyoshi, Takahisa Suzuki, Akitomo Okada, Tomohiro Koga, Shin-ya Kawashiri, Keita Fujikawa, Takashi Igawa, Toshiyuki Aramaki, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Akinari Mizokami, Tomoki Origuchi, Yukitaka Ueki, Katsumi Eguchi, Atsushi Kawakami   +24 more
doaj   +1 more source